Correlation Between PTC Therapeutics and Hepion Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both PTC Therapeutics and Hepion Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PTC Therapeutics and Hepion Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between PTC Therapeutics and Hepion Pharmaceuticals, you can compare the effects of market volatilities on PTC Therapeutics and Hepion Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PTC Therapeutics with a short position of Hepion Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of PTC Therapeutics and Hepion Pharmaceuticals.

Diversification Opportunities for PTC Therapeutics and Hepion Pharmaceuticals

-0.82
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between PTC and Hepion is -0.82. Overlapping area represents the amount of risk that can be diversified away by holding PTC Therapeutics and Hepion Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hepion Pharmaceuticals and PTC Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PTC Therapeutics are associated (or correlated) with Hepion Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hepion Pharmaceuticals has no effect on the direction of PTC Therapeutics i.e., PTC Therapeutics and Hepion Pharmaceuticals go up and down completely randomly.

Pair Corralation between PTC Therapeutics and Hepion Pharmaceuticals

Given the investment horizon of 90 days PTC Therapeutics is expected to generate 0.16 times more return on investment than Hepion Pharmaceuticals. However, PTC Therapeutics is 6.25 times less risky than Hepion Pharmaceuticals. It trades about 0.13 of its potential returns per unit of risk. Hepion Pharmaceuticals is currently generating about -0.27 per unit of risk. If you would invest  4,577  in PTC Therapeutics on December 28, 2024 and sell it today you would earn a total of  922.00  from holding PTC Therapeutics or generate 20.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

PTC Therapeutics  vs.  Hepion Pharmaceuticals

 Performance 
       Timeline  
PTC Therapeutics 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in PTC Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, PTC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
Hepion Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Hepion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

PTC Therapeutics and Hepion Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with PTC Therapeutics and Hepion Pharmaceuticals

The main advantage of trading using opposite PTC Therapeutics and Hepion Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PTC Therapeutics position performs unexpectedly, Hepion Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hepion Pharmaceuticals will offset losses from the drop in Hepion Pharmaceuticals' long position.
The idea behind PTC Therapeutics and Hepion Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance